Thus, the synergistic antiproliferative effect of the combined inhibition of CDK2 and CDK4/6 in breast cancer can overcome acquired resistance to CDK4/6 inhibitors by enhancing senescence (15). The gene discussed is CDK2; the disease is breast cancer.